Innovita Biological Technology Co., Ltd. (SHA:688253)
China · Delayed Price · Currency is CNY 51.03
+2.33 (4.78%)
Nov 5, 2026, 4:00 PM EST
SHA:688253 Revenue
Innovita Biological Technology had revenue of 75.85M CNY in the quarter ending September 30, 2026, with 40.54% growth. This brings the company's total for the last twelve months to 308.21M, down -28.48% year-over-year. In the year 2025, Innovita Biological Technology had annual revenue of 422.03M, down -32.08%. That makes Innovita Biological Technology the 28,522nd largest company in the world by revenue and 4,866th in China.
Revenue (ttm)
308.21M
Revenue Growth
-28.48%
P/S Ratio
22.38
Revenue / Employee
650.23K
Employees
474
Market Cap
6.88B
Revenue by Geography
- East China 123.74M 29.3%
- Southwest China 71.07M 16.8%
- North China 64.60M 15.3%
- South China 53.43M 12.7%
- Central China 37.86M 9.0%
- Northwest China 34.61M 8.2%
- Northeast China 24.89M 5.9%
- Overseas (including Hong Kong, Macao and Taiwan) 11.82M 2.8%
Fiscal year ended Dec 31, 2025 See the full SHA:688253 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 422.03M | -199.36M | -32.08% |
| Dec 31, 2024 | 621.39M | 143.37M | 29.99% |
| Dec 31, 2023 | 478.02M | 31.40M | 7.03% |
| Dec 31, 2022 | 446.62M | 119.71M | 36.62% |
| Dec 31, 2021 | 326.91M | -710.19M | -68.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.